ALX Oncology Holdings Inc. (ALXO)
After hours:
| Previous Close | 8.80 |
| Open | 8.74 |
| Bid | 9.24 x 200 |
| Ask | 9.30 x 200 |
| Day's Range | 8.57 - 9.29 |
| 52 Week Range | 3.94 - 17.83 |
| Volume | |
| Avg. Volume | 659,861 |
| Market Cap | 483.489M |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on Friday, June 7, 2024, at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block
- GlobeNewswire
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows: Format: Fireside chat with analyst, Michael Yee and 1x1 Investor MeetingsDate: Wednesday, June 5, 2024 Time: 1:00 PM ET Location: New York, NY We
- GlobeNewswire
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “We entered the quarter with a great deal of momentum having achieved a key validating development milestone for our platform asset evorpacept in Q4 2023 b
